Matrix Proteinases

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 181-198

  Clark, Ian M ^a   Murphy, Gillian ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72149090444     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50012-1     Document Type: Chapter

References (202)

1. Dunn B.M. Structure and function of the aspartic proteinases. Genetics, structures and mechanisms. Adv. Exp. Med. Biol. 1990, 306:1-585.
2. Handley C.J., Mok M.T., Ilic M.Z., Adcocks C., Buttle D.J., Robinson H.C. Cathepsin D cleaves aggrecan at unique sites within the interglobular domain and chondroitin sulfate attachment regions that are also cleaved when cartilage is maintained at acid pH. Matrix Biol. 2001, 20:543-553.
3. Hembry R.M., Knight C.G., Dingle J.T., Barrett A.J. Evidence that extracellular cathepsin D is not responsible for the resorption of cartilage matrix in culture. Biochim. Biophys. Acta 1982, 714:307-312.
4. Goto T., Kiyoshima T., Moroi R., Tsukuba T., Nishimura Y., Himeno M., Yamamoto K., Tnaka T. Localisation of cathepsins B, cathepsins D and cathepsins L in rat osteoclast by immunolight and immunoelectron microscopy. Histochemistry 1994, 101:33-40.
5. Duffy J.M., Walker B., Guthrie D., Grimshaw J., McNally G., Grimshaw J.T., Spedding P.L., Mollan R.A.B. The detection, quantification and partial characterisation of cathepsin B-like activity in human pathological synovial fluids. Eur. J. Clin. Chem. Clin. Biochem. 1994, 32:429-434.
6. Ikeda Y., Ikata T., Mishiro T., Nakano S., Ikebe M., Yasuoka S. Cathepsins B and L in synovial fluids from patients with rheumatoid arthritis and the effect of cathepsin B on the activation of pro-urokinase. J. Med. Invest. 2000, 47:61-75.
7. Aisa M.C., Rahman S., Senin U., Maggio D., Russell R.G.G. Cathepsin B activity in normal human osteoblast-like cells and human osteoblastic osteosarcoma cells (MG-63)-regulation by interluekin-1-beta and parathyroid hormone. Biochim. Biophys. Acta 1996, 1290:29-36.
8. Maciewicz R.A., Wotton S.F., Etherington D.J., Duance V.C. Susceptibility of the cartilage collagens type II, type IX and type XI to degradation by the cysteine proteinases, cathepsin B and cathepsin L. FEBS Lett. 1990, 269:189-193.
9. Brömme D., Okamoto K., Wang B.B., Biroc S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. J. Biol. Chem. 1996, 271:2126-2132.
10. Maciewicz R.A., Wotton S.F. Degradation of cartilage matrix components by the cysteine proteinases, cathepsin B and cathepsin L. Biomed. Biochim. Acta 1991, 50:561-564.
11. Lang A., Horler D., Baici A. The relative importance of cysteine peptidases in osteoarthritis. J. Rheumatol. 2000, 27:1970-1979.
12. Baici A., Lang A., Horler D., Kissling R., Merlin C. Cathepsin B in osteoarthritis-cytochemical and histochemical analysis of human femoral head cartilage. Ann. Rheum. Dis. 1995, 54:289-297.
13. Buttle D.J., Handley C.J., Ilic M.Z., Saklatvala J., Murata M., Barrett A.J. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin B and an inhibitor of matrix metalloproteinases-evidence for 2 converging pathways of chondrocytemediated proteoglycan degradation. Arth. Rheum. 1993, 36:1709-1717.
14. Sires U.I., Schmid T.M., Fliszar C.J., Wang Z.Q., Gluck S.L., Welgus H.G. Complete degradation of type X collagen requires the combined action of interstitial collagenase and osteoclastderived cathepsin B. J. Clin. Invest. 1995, 95:2089-2095.
15. Hill P.A., Buttle D.J., Jones S.J., Boyde A., Murata M., Reynolds J.J., Meikle M.C. Inhibition of bone resorption by selective in activators of cysteine proteinases. J. Cell. Biochem. 1994, 56:118-130.
16. Debari K., Sasaki T., Udagawa N., Rifkin B.R. An ultrastructural evaluation of the effects of cysteine proteinases inhibitors on osteoclastic resorptive functions. Calcif. Tiss. Int. 1995, 56:566-570.
17. Bossard M.J., Thaddeus T.A., Thompson S.K., Amegadzie B.Y., Hannings C.R., Jones C., Kurdyla J.T., McNulty D.E., Drake F.H., Gowen M., Levy M.A. Proteolytic activity of human osteoclast cathepsin K. J. Biol. Chem. 1996, 271:12517-12524.
18. Garnero P., Borel O., Byrjalsen I., Ferreras M., Drake F.H., McQueney M.S., Foged N.T., Delmas P.D., Delaisse J.M. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. 1998, 273:32347-32352.
19. Kafienah W., Bromme D., Buttle D.J., Croucher L.J., Hollander A.P. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochem. J. 1998, 331:727-732.
20. Li Z., Hou W.S., Bromme D. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Biochemistry 2000, 39:529-536.
21. Li Z., Hou W.S., Escalante-Torres C.R., Gelb B.D., Bromme D. Collagenase activity of cathepsin K depends on complex formation with chondroitin sulfate. J. Biol. Chem. 2002, 277:28669-28676.
22. Li Z., Yasuda Y., Li W., Bogyo M., Katz N., Gordon R.E., Fields G.B., Bromme D. Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J. Biol. Chem. 2004, 279:5470-5479.
23. Votta B.J., Levy M.A., Badger A., Bradbeer J., Dodds R.A., James I.E., Thompson S., Bossard M.J., Carr T., Connor J.R., Tomaszek T.A., Szewczuk L., Drake F.H., Veber D.F., Gowen M. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. J. Bone Min. Res. 1997, 12:1396-1406.
24. Inui T., Ishibashi O., Inaoka T., Origane Y., Kumegawa M., Kokubo T., Yamamura T. Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J. Biol. Chem. 1997, 272:8109-8112.
25. Drake F.H., Dodds R.A., James I.E., Connor J.R., Debouck C., Richardson S., Leerykaczewski E., Coleman L., Rieman D., Barthlow R., Hastings G., Gowen M. Cathepsin K, but not cathepsin B, cathepsin L or cathepsin S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 1996, 271:12511-12516.
26. Gelb B.D., Shi G.P., Chapman H.A., Desnick R.J. Pycnodyostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996, 273:1236-1238.
27. Hou W.S., Li W., Keyszer G., Weber E., Levy R., Klein M.J., Gravallese E.M., Goldring S.R., Bromme D. Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. Arthritis Rheum. 2002, 46:663-674.
28. Hou W.S., Li Z., Buttner F.H., Bartnik E., Bromme D. Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol. Chem. 2003, 384:891-897.
29. Konttinen Y.T., Mandelin J., Li T.F., Salo J., Lassus J., Liljestrom M., Hukkanen M., Takagi M., Virtanen I., Santavirta S. Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 2002, 46:953-960.
30. Barrett A.J. The cystatins: a new class of peptidase inhibitors. Trends Biochem. Sci. 1987, 12:193-196.
31. Lerner U.H., Johansson L., Ransjo M., Rosenquist J.B., Reinholt F.P., Grubb A. Cystatin C, an inhibitor of bone resorption produced by osteoblasts. Acta Phys. Scand. 1997, 161:81-92.
32. Ménard H.A., El-Amine M. The calpain-calpastatin system in rheumatoid arthritis. Immunol. Today 1996, 17:545-547.
33. Yamamoto S., Shimizu K., Niibayashi H., Yasuda T., Yamamuro T. Immunocytochemical demonstration of calpain in synovial cells in human arthritic synovial joints. Biomed. Res. 1994, 15:77-88.
34. Szomor Z., Shimizu K., Yamamoto S., Yasuda T., Ishikawa H., Nakamura T. Externalization of calpain (calcium-dependent neutral cysteine proteinase) in human arthritic cartilage. Clin. Exp. Rheumatol. 1999, 17:569.
35. Szomor Z., Shimizu K., Fujimori Y., Yamamoto S., Yamamuro T. Appearance of calpain correlates with arthritis and cartilage destruction in collagen-induced arthritic knee joints of mice. Ann. Rheum. Dis. 1995, 54:477-483.
36. Oshita H., Sandy J.D., Suzuki K., Akaike A., Bai Y., Sasaki T., Shimizu K. Mature bovine articular cartilage contains abundant aggrecan that is C-terminally truncated at Ala719-Ala720, a site which is readily cleaved by m-calpain. Biochem. J. 2004, 382:253-259.
37. Despres N., Talbot G., Plouffe B., Boire G., Menard H.A. Detection and expression of a cDNA clone that encodes a polypeptide containing 2 inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J. Clin. Invest. 1995, 95:1891-1896.
38. Salvesen G., Enghild J.J. Zymogen activation, specificity and genomic structures of human neutrophil elastase and cathepsin G reveal a new branch of the chymotrypsinogen superfamily of serine proteinases. Biomed. Biochim. Acta 1991, 50:665-671.
39. Starkey P.M., Barrett A.J., Burleigh M.C. The degradation of articular collagen by neutrophil proteinases. Biochim. Biophys. Acta 1977, 483:386-397.
40. Rao N.V., Wehner N.G., Marshall B.C., Gray W.R., Gray B.H., Hoidal J.R. Characterisation of proteinase-3 (PR-3), a neutrophil serine proteinase. J. Biol. Chem. 1991, 266:9540-9548.
41. McDonnell J., Lobner J.M., Knight W.B., Lark M.W., Green B., Poe M., Moore V.L. Comparison of the proteoglycanolytic activities of human leukocyte elastase and human cathepsin G in vitro and in vivo. Connect. Tissue Res. 1993, 30:1-9.
42. Kafienah W., Buttle D.J., Burnett D., Hollander A.P. Cleavage of native type I collagen by human neutrophil elastase. Biochem. J. 1998, 330:897-902.
43. Campanelli D., Melchior M., Fu Y.P., Nakata M., Shuman H., Nathan C., Gabay J.E. Cloning of a cDNA for proteinase 3: A serine protease, antibiotic, and autoantigen from human neutrophils. J. Exp. Med. 1990, 172:1709-1715.
44. Schalkwijk J., Joosten L.A.B., Van den Berg W.B., Van de Putte L.B.A. Antigen-induced arthritis in beige (Chediak-Higashi) mice. Ann. Rheum. Dis. 1990, 49:607-610.
45. Pettipher E.R., Henderson B., Hardingham T.E., Ratcliffe A. Cartilage proteoglycan depletion in acute and chronic antigen-induced arthritis. Arth. Rheum. 1989, 32:601-607.
46. Potempa J., Korzus E., Travis J. The serpin superfamily of proteinase inhibitors: structure function and regulation. J. Biol. Chem. 1994, 269:15957-15960.
47. Thompson R.C., Ohlsson K. Isolation, properties and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc. Natl Acad. Sci. USA 1986, 83:6692-6696.
48. Gotis-Graham I., Hogg P.J., McNei H.P. Significant correlation between thrombospondin 1 and serine proteinase expression in rheumatoid synovium. Arth. Rheum. 1997, 40:1780-1787.
49. 1-antichymotrypsin and antithrombin III by matrix metalloproteinases-1 (tissue collagenase),-2 (72-kDa gelatinase/type IV collagenase), and-3 (stromelysin). J. Biol. Chem. 1991, 266:15810-15816.
50. Okada Y., Watanabe S., Nakanishi I., Kishi J., Hayakawa T., Watorek W., Travis J., Nagase H. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett. 1988, 229:157-160.
51. Dano K., Andreasen P.A., Grondahl-Hansen J., Kristensen P., Nielsen L.S., Skriver L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 1985, 44:139-266.
52. Saksela O., Rifkin D.B. Cell-associated plasminogen activation: regulation and physiological functions. Ann. Rev. Cell Biol. 1988, 4:93-126.
53. Ellis V., Behrendt N., Dano K. Plasminogen activation by receptor-bound urokinase: a kinetic study with both cell-associated and isolated receptor. J. Biol. Chem. 1991, 266:12752-12758.
54. Andreasen P.A., Georg B., Lund L.R., Riccio A., Stacey S.N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell Endocrinol. 1990, 68:1-19.
55. Blasi F., Vassalli J-D., Dano K. Urokinase-type plasminogen activator: proenzyme, receptor and inhibitors. J. Cell Biol. 1987, 104:801-804.
56. Chapman H.A., Stone O.L. Characterisation of a macrophage-derived plasminogen-activator inhibitor. Similarities with placental urokinase inhibitor. Biochem. J. 1985, 230:109-116.
57. Kruithof E.K.O. Plasminogen activator inhibitors-a review. Enzyme 1988, 40:113-121.
58. 2-macro globulin receptor. J. Biol. Chem. 1994, 269:17886-17892.
59. Belcher C., Fawthrop F., Bunning R., Doherty M. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann. Rheum. Dis. 1996, 55:230-236.
60. Ronday H.K., Smits H.H., Van Muijen G.N.P., Pruszczynski M.S.M., Van Langelaan E.J., Breedveld F.C., Verheijen J.H. Difference in expression of the plasminogen activator system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Brit. J. Rheumatol. 1996, 35:416-423.
61. Busso N., Peclat V., So A., Sappino A.P. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann. Rheum. Dis. 1997, 56:550-557.
62. Lajeunesse D. The role of bone in the treatment of osteoarthritis. Osteoarthritis Cartilage 2004, 12(Suppl A):S34-S38.
63. 2-macroglobulin and TIMP. Inflammation Res. 1996, 45:464-472.
64. Saito S., Katoh M., Matsumoto M., Matsumoto S., Masuho Y. Collagen de gradation induced by the combination of IL-1 ? and plasminogen in rabbit articular cartilage explant culture. J. Biochem. 1997, 122:49-54.
65. Milner J.M., Elliott S.F., Cawston T.E. Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways. Arthritis Rheum 2001, 44:2084-2096.
66. Vignon E., Mathieu P., Ejui J., Descotes J., Hartmann D., Patricot L.M., Richard M. Study of an inhibitor of plasminogen activator (tranexamic acid) in the treatment of experimental osteo arthritis. J. Rheumatol. 1991, 18(Suppl 27):131-133.
67. van der Laan W.H., Ronday H.K., TeKoppele J.M., Breedveld F.C., Huizinga T.W., Verheijen J.H. No therapeutic effect of plasmin antagonist tranexamic acid in rheumatoid arthritis. A double-blind placebo-controlled pilot study. Clin. Exp. Rheumatol. 2003, 21:359-362.
68. Yang Y.H., Carmeliet P., Hamilton J.A. Tissue-type plasminogen activator deficiency exacerbates arthritis. J. Immunol. 2001, 167:1047-1052.
69. Van Ness K., Chobaz-Peclat V., Castellucci M., So A., Busso N. Plasminogen activator inhibitor type-1 deficiency attenuates murine antigen-induced arthritis. Rheumatology 2002, 41:136-141.
70. Cook A.D., Braine E.L., Campbell I.K., Hamilton J.A. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am. J. Pathol. 2002, 160:917-926.
71. Martin T.J., Allan E.H., Fukumoto S. The plasminogen activator and inhibitor system in bone remodeling. Growth Regulation 1993, 3:209-214.
72. Hoekman K., Lowik C.W.G.M., Van Derruit M., Bijvoet O.L.M., Verheijen J.H., Papapoulos S.E. Regulation of the production of plasminogen activators by bone resorption-enhancing and inhibiting factors in 3 types of osteoblast-like cells. Bone Min. 1991, 14:189-204.
73. Leloup G., Lemoine P., Carmeliet P., Vaes G. Bone resorption and response to calcium regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor. J. Bone Min. Res. 1996, 11:1146-1157.
74. Tumber A., Papaioannou S., Breckon J., Meikle M.C., Reynolds J.J., Hill P.A. The effects of serine proteinase inhibitors on bone resorption in vitro. J. Endocrinol. 2003, 178:437-447.
75. Daci E., Everts V., Torrekens S., Van Herck E., Tigchelaar-Gutter W., Bouillon R., Carmeliet G. Increased bone formation in mice lacking plasminogen activators. J. Bone. Miner. Res. 2003, 18:1167-1176.
76. Suzuki K., Lees M., Newlands G.F.J., Nagase H., Woolley D.E. Activation of precursors for matrix metalloproteinases 1 (interstitial collagenase) and 3 (stromelysin) by rat mast cell proteinases I and II. Biochem. J. 1995, 305:301-306.
77. Tetlow L.C., Woolley D.E. Distribution, activation and tryptase chymase phenotype of mast cells in the rheumatoid lesion. Ann. Rheum. Dis. 1995, 54:549-555.
78. Froelich C.J., Zhang X.L., Turbov J., Hudig D., Winkler U., Human W.L. Human granzyme B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes. J. Immunol. 1993, 151:7161-7171.
79. Ronday H.K., van der Laan W.H., Tak P.P., de Roos J.A., Bank R.A., TeKoppele J.M., Froelich C.J., Hack C.E., Hogendoorn P.C., Breedveld F.C., Verheijen J.H. Human granzyme B mediates cartilage proteoglyc an degradation and is expressed at the invasive front of the synovium in rheumatoid arthritis. Rheumatology 2001, 40:55-61.
80. Horiuchi K., Saito S., Sasaki R., Tomatsu T., Toyama Y. Expression of granzyme B in human articular chondrocytes. J. Rheumatol 2003, 30:1799-1810.
81. Tak P.P., Kumer J.A., Hack C.E., Daha M.R., Smeets T.J.M., Erkelens G.W. Granzyme-positive cytotoxic cells are specifically increased in early rheumatoid synovial tissue. Arth. Rheum. 1994, 12:1735-1743.
82. Tak P.P., Spaeny-Dekking L., Kraan M.C., Breedveld F.C., Froelich C.J., Hack C.E. The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin. Exp. Immunol. 1999, 116:366-370.
83. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997, 91:439-442.
84. Kessler E., Takahara K., Biniaminov L., Brusel M., Greenspan D.S. Bone morphogenetic protein-1: The type 1 procollagen C-proteinase. Science 1996, 271:360-362.
85. Sarras M.P. BMP-1 and the astacin family of metalloproteinases: A potential link between the extracellular matrix, growth factors and pattem formation. BioEssays 1996, 18:439-442.
86. Moss M.L., White J.M., Lambert J.H., Andrews R.C. TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today 2001, 6:417-426.
87. Ohta S., Harigai M., Tanaka M., Kawaguchi Y., Sugiura T., Takagi K., Fukasawa C., Hara M., Kamatani N. Tumour necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis. J. Rheumatol. 2001, 28:1756-1763.
88. Patel I.R., Attur M.G., Patel R.N., Stuchin S.A., Abagyan R.A., Abramson S.B., Amin A.R. TNF-alpha convertase enzyme from human arthritis-affected cartilage: isolation of cDNA by differential display, expression of the active enzyme, and regulation of TNF-alpha. J. Immunol. 1998, 160:4570-4579.
89. Amin A.R. Regulation of tumour necrosis factor-alpha and tumour necrosis factor converting enzyme in human osteoarthritis. Osteoarthritis Cartilage 1999, 7:392-394.
90. Bohm B.B., Aigner T., Gehrsitz A., Blobel C.P., Kalden J.R., Burkhardt H. Up regulation of MDC1 5 (metargidin) messenger RNA in human osteoarthritic cartilage. Arthritis Rheum. 1999, 42:1946-1950.
91. Chubinskaya S., Cs-Szabo G., Kuettner K.E. ADAM-10 message is expressed in human articular cartilage. J. Histochem. Cytochem 1998, 46:723-729.
92. Chubinskaya S., Mikhail R., Deutsch A., Tindal M.H. ADAM-10 protein is present in human articular cartilage primarily in the membrane-bound from and is upregulated in response to IL-1 alpha in bovine nasal cartilage. J. Histochem. Cytochem. 2001, 49:1165-1176.
93. McKie N., Edwards T., Dallas D.J., Houghton A., Stringer B., Graham R., Russell G., Croucher P.I. Expression of members of a novel membrane linked metalloproteinase family (ADAM) in human articular chondrocytes. Biochem. Biophys. Res. Commun. 1997, 230:335-339.
94. Flannery C.R., Little C.B., Caterson B., Hughes C.E. Effects of culture conditions and exposure to catabolic stimulators (IL-1 and retinoic acid) on the expression of matrix metalloproteinases (MMPs) and disintegrin metalloproteinases (ADAMs) by articular cartilage chondrocytes. Matrix Biol. 1999, 18:225-237.
95. Inoue D., Reid M., Lum L., Kratzschmar J., Weskamp G., Myung Y.M., Baron R., Blobel C.P. Cloning and initial characterization of mouse meltrin beta and analysis of the expression of four metalloprotease-disintegrins in bone cells. J. Biol. Chem. 1998, 273:4180-4187.
96. Verrier S., Hogan A., McKie N., Horton M. ADAM gene expression and regulation during human osteoclast formation. Bone 2004, 35:34-46.
97. Wolfsberg T.G., Primakoff P., Myles D.G., White J.M. ADAMs, membrane proteins containing a disintegrin and metalloprotease domain - multipotential roles in cell-cell and cell-matrix interaction. J Cell Biol. 1995, 131:275-278.
98. Apte S.S. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int. J. Biochem. Cell Biol. 2004, 36:981-985.
99. Collins-Racie L.A., Flannery C.R., Zeng W., Corcoran C., Annis-Freeman B., Agostino M.J., Arai M., DiBlasio-Smith E., Domer A.J., Georgiadis K.E., Jin M., Tan X.Y., Morris E.A., LaVallie E.R. ADAMTS-8 exhibits a ggrecanase activity and is expressed in human articular cartilage. Matrix Biol. 2004, 23:219-230.
100. Sandy J.D., Flannery C.R., Neame P.J., Lohmander L.S. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu373-Ala374 bond of the interglobular domain. J Clin. Invest. 1992, 89:1512-1516.
101. Lark M.W., Bayne E.K., Flanagan J., Harper C.F., Hoermer L.A., Hutchinson N.I., Singer I.L., Donatelli S.A., Weidner J.R., Williams H.R., Mumford R.A., Lohmander L.S. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic and rheumatoid. J. Clin. Invest. 1997, 100:93-106.
102. Singer I.I., Scott S., Kawka D.W., Bayne E.K., Weidner J.R., Williams H.R., Mumford R.A., Lark M.W., McDonnell J., Christen A.J., Moore V.L., Mudgett J.S., Visco D.M. Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis. Osteoarthritis Cartilage 1997, 5:407-418.
103. Van Meurs J.B., van Lent P.L., Holthuysen A.E., Singer I.I., Bayne E.K., van den Berg W.B. Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum. 1999, 42:1128-1139.
104. Matthews R.T., Gary S.C., Zerillo C., Pratta M., Solomon K., Arner E.C., Hockfield S. Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J. Biol. Chem. 2000, 275:22695-22703.
105. Sandy J.D., Westling J., Kenagy R.D., Iruela-Arispe M.L., Verscharen C., Rodriguez-Mazaneque J.C., Zimmermann D.R., Lemire J.M., Fischer J.W., Wight T.N., Clowes A.W. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J. Biol. Chem. 2001, 276:13372-13378.
106. Tortorella M.D., Malfait A.M., Deccico C., Amer E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001, 9:539-552.
107. Malfait A.M., Liu R.Q., Ijiri K., Komiya S., Tortorella M.D. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J. Biol. Chem. 2002, 277:22201-22208.
108. Yamanishi Y., Boyle D.L., Clark M., Maki R.A., Tortorella M.D., Arner E.C., Firestein G.S. Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J. Immunol. 2002, 168:1405-1412.
109. Vankemmelbeke M.N., Holen I., Wilson A.G., Ilic M.Z., Handley C.J., Kelner G.S., Clark M., Liu C., Maki R.A., Burnett D., Buttle D.J. Expression and activity of ADAM-TS5 in synovium. Eur. J. Biochem. 2001, 268:1259-1268.
110. Sugimoto K., Takahashi M., Yamamoto Y., Shimada K., Tanzawa K. Identification of aggrecanase activity in medium of cartilage culture. J. Biochem. 1999, 126:449-455.
111. Tortorella M.D., Pratta M., Liu R.Q., Austin J., Ross O.H., Abbaszade I., Burn T., Arner E. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J. Biol. Chem. 2000, 275:18566-18573.
112. Kashiwagi M., Enghild J.J., Gendron C., Hughes C., Caterson B., Itoh Y., Nagase H. Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J. Biol. Chem. 2004, 279:10109-10119.
113. Gao G., Plaas A., Thompson V.P., Jin S., Zuo F., Sandy J.D. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J. Biol. Chem. 2004, 279:10042-10051.
114. Pratta M.A., Tortorella M.D., Arner E. Age-related changes in aggrecan glycosylation affect cleavage by aggreanase. J. Biol. Chem. 2000, 275:39096-39102.
115. Brinckerhoff C.E., Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nature Rev. Mol. Cell Biol. 2002, 3:207-214.
116. 1 within collagen IV are protected against gelatinase A attack in the native protein. J. Biol. Chem. 1996, 271:30964-30970.
117. Nagase H. Human stromelysins 1 and 2. Methods Enzymol. 1995, 248:449-470.
118. Borkakoti N., Winkler F.K., Williams D.H., D'Arcy A., Broadhurst M.J., Brown P.S., Johnson W.H., Murray E.J. Structure of the catalytic domain of human fibroblast collagenase complexed with an inhibitor. Nat. Struct. Biol. 1994, 1:106-110.
119. Spurlino J.C., Smallwood A.M., Carlton D.D., Banks T.M., Vavra K.J., Johnson J.S., Cook E.R., Falvo J., Wahl R.C., Pulvino T.A., Wendoloski J.J., Smith D.L. 1.56 A structure of mature truncated human fibroblast collagenase. Proteins 1994, 19:98-109.
120. Lovejoy B., Cleasby A., Hassell A.M., Longley K., Luther M.A., Weigl D., McGeehan G., McElroy A.B., Drewry D., Lambert M.H., Jordan S.R. Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. Science 1994, 263:375-377.
121. Dhanaraj V., Ye Q.Z., Johnson L.L., Hupe D.J., Ortwine D.F., Dubar J.B., Rubin J.R., Pavlovsky A., Humblet C., Blundell T.L. X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily. Structure 1996, 4:375-386.
122. Stams T., Spurlino J.C., Smith D.L., Wahl R.C., Ho T.F., Qoronfleh M.W., Banks T.M., Rubin B. Structure of human neutrophil collagenase reveals large S1? specificity pocket. Nat. Struct. Biol. 1994, 1:119-123.
123. Bode W., Reinemer P., Huber R., Kleine T., Schnierer S., Tschesche H. The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J 1994, 13:1263-1269.
124. Grams F., Reinemer P., Powers J.C., Kleine T., Pieper M., Tschesche H., Huber R., Bode W. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design. Eur. J. Biochem. 1995, 228:830-841.
125. Rowsell S., Hawtin P., Minshull C.A., Jepson H., Brockbank S.M., Barratt D.G., Slater A.M., McPheat W.L., Waterson D., Henney A.M., Pauptit R.A. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 2002, 319:173-181.
126. Borkakoti N. Matrix metalloprotease inhibitors; design from structure. Biochem. Soc. Trans. 2004, 32:17-20.
127. Gooley P.R., O'Connell J.F., Marcy A.I., Cuca G.C., Salowe S.P., Bush B.L., Hermes J.D., Esser C.K., Hagmann W.K., Springer J.P., Johnson B.A. The NMR structure of the inhibited catalytic domain of human stromelysin-1. Nat. Struct. Biol. 1994, 1:111-118.
128. Morgunova E., Tuuttila A., Bergmann U., Isupov M., Lindqvist Y., Schneider G., Tryggyvason K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999, 284:1667-1670.
129. Li J., Brick P., O'Hare M.C., Skarzynski T., Lloyd L.F., Curry V.A., Clark I.M., Bigg H.F., Hazleman B.L., Cawston T.E., Blow D.M. Structrue of full-length porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed propeller. Structure 1995, 3:541-549.
130. De Souza S.J., Brentani R.R. On the structure/function relationship of polymorphonuclear-leucocyte collagenase. Biochem. J. 1994, 300:605.
131. Chung L., Dinakarpandian D., Yoshida N., Lauer-Fields J.L., Fields G.B., Visse R., Nagase H. Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J. 2004, 23:3020-3030.
132. Gomis-Rüth F.X., Gohlke U., Betz M., Knäuper V., Murphy G., López-Otín C., Bode W. The helping hand of collagenase-3 (MMP-13): 2,7 crystal structure of its C-terminal haemopex in-like domain. J. Mol. Biol. 1996, 264:556-566.
133. Gohlke U., Gomis-Rüth F.X., Crabbe T., Murphy G., Docherty A.J.P., Bode W. The C-terminal (haemopexinlike) domain structure of human gelatinase A (MMP2): Structural implications for its function. FEBS Lett. 1996, 378:126-130.
134. Morgunova E., Tuuttila A., Bergmann U., Tryggvason K. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2. Proc. Natl. Acad. Sci. USA 2002, 99:7414-7419.
135. Clark I.M., Cawston T.E. Fragments of human fibroblast collagenase: purification and characterisation. Biochem. J. 1989, 263:201-206.
136. Murphy G., Allan J.A., Willenbrock F., Cockett M.I., O'Connell J.P., Docherty A.J.P. The role of the C-terminal domain in collagenase and stromelysin specificity. J. Biol. Chem. 1992, 267:9612-9618.
137. Hirose T., Patterson C., Pourmotabbed T., Mainardi C.L., Hasty K.A. Structure-function relationship of human neutrophil collagenase: identification of regions responsible for substrate specificity and general proteinase activity. Proc. Natl. Acad. Sci. USA 1993, 90:2569-2573.
138. Murphy G., Willenbrock F., Ward R.V., Cockett M.I., Eaton D., Docherty A.J.P. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem. J. 1992, 283:637-641.
139. Baragi V.M., Fliszar C.J., Conroy M.C., Ye Q.-Z., Shipley J.M., Welgus H.G. Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrily sin exhibit equally compromised binding affinities as compared to full-length stromelysin. J. Biol. Chem. 1994, 269:12692-12697.
140. Knäuper V., Osthues A., DeClerck Y.A., Langley K.E., Blaser J., Tschesche H. Fragmentation of human polymorphonuclear leukocyte collagenase. Biochem. J. 1993, 291:847-854.
141. Butler G.S., Butler M.J., Atkinson S.J., Will H., Tamura T., van Westrum S.S., Crabbe T., Clements J., d'Ortho M.P., Murphy G. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelationase, A. A kinetic study. J. Biol. Chem. 1998, 273:871-880.
142. Frisch S.M., Morisaki J.H. Positive and negative transcriptional elements of the type IV collagenase gene. Mol. Cell. Biol. 1990, 10:6524-6532.
143. Jonat C., Rahmsdorf H.J., Park K.K., Cato A.C.B., Gebel S., Ponta H., Herrlich P. Anti-tumor promotion and anti-inflammation-down modulation of AP-1 (Fos, Jun) activity by glucocorticoid hormone. Cell 1990, 62:1189-1204.
144. Nicholson R.C., Mader S., Nagpal S., Leid M., Rochette-Egly C., Chambon P. Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J 1990, 9:4443-4454.
145. Springman E.B., Angleton E.L., Birkedal-Hansen H., Van Wart H.E. Multiple modes of activation of latent human fibroblast collagenase-evidence for the role of a cys-73 active site zinc complex in latency and a cysteine switch mechanism for activation. Proc. Natl Acad. Sci. USA 1990, 87:364-368.
146. Pei D., Weiss S.J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995, 375:244-247.
147. Crabbe T., Ioannou C., Docherty A.J.P. Human progelatinase A can be activated by autolysis at a rate that is concentrationdependent and enhanced by heparin bound to the C-terminal domain. Eur. J. Biochem. 1993, 218:431-438.
148. Murphy G., Knäuper V. Relating matrix metalloproteinase structure to function: Why the "hemopexin" domain. Matrix Biol. 1997, 15:511-518.
149. Okada Y., Morodomi T., Enghild J.J., Suzuki K., Yasui A., Nakanishi I., Salvesen G., Nagase H. Matrix metalloproteinase, 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur. J. Biochem. 1990, 194:721-730.
150. Hipps D.S., Hembry R.M., Docherty A.J.P., Reynolds J.J., Murphy G. Purification and characterisation of human 72-kDa gelatinase (type IV) collagenase. Use of immunolocalisation to demonstrate the non-coordinated regulation of the 72-kDa and 95-kDa gelatinases by human fibroblasts. Biol. Chem. Hoppe-Seyler 1991, 372:287-296.
151. Cowell S., Knäuper V., Stewart M.L., d'Ortho M.P., Stanton H., Hembry R.M., Lopez-Otin C., Reynolds J.J., Murphy G. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation, of gelatinase A, gelatinase B and collagenase 3. Biochem. J. 1998, 331:453-458.
152. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 2002, 115:3719-3727.
153. Docherty A.J.P., Lyons A., Smith B.J., Wright E.M., Stephens P.E., Harris T.J.R., Murphy G., Reynolds J.J. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985, 318:66-69.
154. Boone T.C., Johnson M.J., De Clerck Y.A., Langley K.E. cDNA cloning and expression of ametalloproteinase inhibitor related to tissue inhibitor of metalloproteinases. Proc. Natl Acad. Sci. USA 1990, 87:2800-2804.
155. rd member of the TIMP family. J. Biol. Chem. 1992, 267:17321-17326.
156. Apte S.S., Hayashi K., Seldin M.F., Mattei M.-G., Hayashi M., Olsen B.R. Gene encoding a novel murine tissue anhibitor of metalloproteinases (TIMP),TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev. Dyn. 1994, 200:177-197.
157. Apte S.S., Mattei M.-G., Olsen B.R. Cloning of the cDNA encoding human tissue inhibitor of metalloproteinases-3 (TIMP-3) and mapping of the TIMP3 gene to chromosome 22. Genomics 1994, 19:86-90.
158. Apte S.S., Olsen B.R., Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J. Biol. Chem. 1995, 270:14313-14318.
159. Leco K.J., Khokha R., Pavloff N., Hawkes S.P., Edwards D.R. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J. Biol. Chem. 1994, 269:9352-9360.
160. Silbiger S.M., Jacobsen V.L., Cupples R.L., Koski R.A. Cloning of cDNAs encoding human TIMP-3, a novel member of the tissue inhibitor of metalloproteinase family. Gene 1994, 141:293-297.
161. Uria J.A., Ferrando A.A., Velasco G., Freije J.M.P., Lopez-Otin C. Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. Cancer Res. 1994, 54:2091-2094.
162. Greene J., Wang M., Liu Y.E., Raymond L.A., Rosen C., Shi Y.E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. Biol. Chem. 1996, 271:30375-30380.
163. Leco K.J., Apte S.S., Taniguchi G.T., Hawkes S.P., Khokha R., Schultz G.A., Edwards D.R. Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett. 1997, 401:213-217.
164. Gomis-Ruth F.x., Maskos K., Betz M., Bergner A., Huber R., Suzuki K., Yoshida N., Nagase H., Breu K., Bourenkov G.P., Bartunik H., Bode W. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 1997, 389:77-81.
165. Wilhelm S.M., Collier I.E., Marmer B.L., Eisen A.Z., Grant G.A., Goldberg G.I. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 1989, 264:17213-17221.
166. Goldberg G.I., Strongin A., Collier I.E., Genrich L.T., Marmer B.L. Interaction of 92-kDA type IV collagenase with the tissue inhibitor of metalloproteinase prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J. Biol. Chem. 1992, 267:4583-4591.
167. Goldberg G.I., Marmer B.L., Grant G.A., Eisen A.Z., Wilhelm S., He C. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc. Natl Acad Sci. USA 1989, 86:8207-8211.
168. Stetler-Stevenson W.G., Krutzsch H.C., Wacher M.P., Margulies I.M.K., Liotta L.A. The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomecurial activation. J. Biol. Chem. 1989, 264:1353-1356.
169. Howard E.W., Bullen E.C., Banda M.J. Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2. J. Biol. Chem. 1991, 266:13064-13069.
170. Murphy G., Houbrechts A., Cocket M.I., Williamson R.A., O'Shea M., Docherty A.J.P. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloprotinase inhibitory activity. Biochemistry 1991, 30:8097-8101.
171. Fridman R., Fuerst R.R., Bird R.E., Hoyhtya M., Oelkuct M., Kraus S., Komarek D., Liotta L.A., Berman M.L., Stetler-Stevenson W.G. Dornain structure of human 72-kDa gelatinase/type, IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding regions. J. Biol. Chem. 1992, 267:15398-15405.
172. Willenbrock F., Crabbe T., Slocombe P.M., Sutton C.W., Docherty A.J.P., Cockett M.L., O'Shea M., Brocklehurst K., Phillips I.R., Murphy G. The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry 1993, 32:4330-4337.
173. Howard E.W., Bullen E.C., Banda M. Preferential inhibition of 72-kDa and 92-kDa gelatinases by tissue, inhibitor of metalloproteinases-2. J. Biol. Chem. 1991, 266:13070-13075.
174. Howard E.W., Banda M.J. Binding of tissue inhibitor of metalloprotein ases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site. J. Biol. Chem. 1991, 266:17972-17977.
175. Kleiner D.E., Tuuttila A., Tryggvason K., Stetler-Stevenson W.G. Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry 1993, 32:1583-1592.
176. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 1995, 270:5331-5338.
177. Murphy G., Ward R., Hembry R.M., Reynolds J.J., Kühn K., Tryggvason K. Characterization of gelatinase from pig polymorphonuclear, leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem. J. 1989, 258:463-472.
178. Ward R.V., Hembry R.M., Reynolds J.J., Murphy G. The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex-demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. Biochem. J. 1991, 278:179-187.
179. Kashiwagi M., Tortorella M., Nagase H., Brew K. TIMP-3 is a potent inhibitor of aggrecanase I (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 2001, 276:12501-12504.
180. Edwards D.R., Leco K.J., Leco P.A., Lim M.S., Phillips B.W., Raja J., Sharma R. Regulation of TIMP gene expression. Inhibitors of Metalloproteinases in Development and Disease 2000, 13-25. Harwood Academic Press, Lausanne, Switzerland. S.P. Hawkes, D.R. Edwards, R. Khokha (Eds.).
181. Young D.A., Phillips B.W., Lundy C., Nuttall R.K., Hogan A., Schultz G.A., Leco K.J., Clark I.M., Edwards D.R. Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene. Biochem. J. 2002, 364:89-99.
182. Takahashi C., Sheng Z., Horan T.P., Kitayama H., Maki M., Hitomi K., Kitaura Y., Takai S., Sasahara R.M., Horimoto A., Ikawa Y., Ratzkin B.J., Arakawa T., Noda M. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci. USA. 1998, 95:13221-13226.
183. 2-macroglobulin interactions. Localization of cleavage sites in the buit regions of five mammalian a-macroglobulins. J. Biol. Chem. 1989, 264:393-401.
184. Tortorella M.D., Arner E.C., Hills R., Easton A., Korte-Sarfaty J., Fok K., Wittwer A.J., Liu R.Q., Malfait A.M. Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J. Biol. Chem. 2004, 279:17554-17561.
185. 2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J 1992, 6:3345-3353.
186. 2-macroglobulin, a multifunctional binding and targeting protein with possible roles in immunity and autoimmunity. Ann. N. Y. Acad. Sci. 1994, 737:267-272.
187. Stephens R.W., Tapiovaara H., Reisberg T., Bizik J., Vaheri A. Alpha-2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. Cell Regul. 1991, 2:1057-1065.
188. Dean D.D., Martel-Pelletier J., Pelletier J-P., Howell D.S., Woessner J.F. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J. Clin. Invest. 1989, 84:678-685.
189. Kevorkian L., Young D.A., Darrah C., Donell S.T., Shepstone L., Porter S., Brockbank S.M., Edwards D.R., Parker A.E., Clark I.M. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum. 2004, 50:131-141.
190. Bau B., Gebhard P.M., Haag J., Knorr T., Bartnik E., Aigner T. Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 2002, 46:2648-2657.
191. Martel-Pelletier J., McCollum R., Fujimoto N., Obata K., Cloutier J-M., Pelletier J-P. Excess of metalloproteases over tissue inhibitor of metalloproteases may contribute to cartilage degradation in oste oarthritis and rheumatoid arthritis. Lab. Invest. 1994, 70:807-815.
192. Cawston T., McLaughlan P., Coughlan R., Kyle V., Hazleman B. Synovial fluids from infected joints, contain metalloproteinasetissue inhibitor of metalloproteinase (TIMP) complexes. Biochim. Biophys. Acta 1990, 1033:96-102.
193. van Lent P.L., Holthuysen A.E., Sloetjes A., Lubberts E., van den Berg W.B. Local overexpression of adeno-viral IL-4 protects cartilage from metallo proteinase-induced destruction during immune complex-mediated arthritis by preventing activation of pro-MMPs. Osteoarthritis Cartilage 2002, 10:234-243.
194. van Meurs J., van Lent P., Holthuysen A., Lambrou D., Bayne E., Singer I., van den Berg W. Active matrix metalloproteinases are present in cartilage during immune complex-mediated arthritis: a pivotal role for stromelysin-1 in cartilage destruction. J. Immunol. 1999, 163:5633-5639.
195. van Meurs J., van Lent P., Stoop R., Holthuysen A., Singer I., Bayne E., Mudgett J., Poole R., Billinghurst C., van der Kraan P., Buma P., van den Berg W. Cleevage of aggrecan at the Asn 341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arth. Rheum. 1999, 42:2074-2084.
196. Ellis A.J., Powell L.K., Curry V.A., Cawston T.E. TIMP-1 and TIMP-2 prevent the release of collagen fragments in cartilage stimulated with IL-1. Biochem. Biophys. Res. Commun. 1994, 201:94-101.
197. Gendron C., Kashiwagi M., Hughes C., Caterson B., Nagase H. TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett. 2003, 555:431-436.
198. Partridge N.C., Walling H.W., Bloch S.R., Omura T.H., Chan P.T., Pearman A.T., Chou W-Y. The regulation and regulatory role of collagenase in bone. Crit. Rev. in Euk. Gene Exp. 1996, 6:15-27.
199. Bord S., Horner A., Hembry R.M., Reynolds J.J., Compston J.E. Distribution of matrix metalloproteinases and their inhibitor, TIMP-1, in developing human osteophytic bone. J. Anatomy 1997, 191:39-48.
200. Hill P.A., Docherty A.J.P., Bottomley K.M., O'Connell J.P., Morphy J.R., Reynolds J.J., Meikle M.C. Inhibition of bone resorption in vitro by selective inhibitors of gelationase and collagenase. Biochem. J. 1995, 308:167-175.
201. Stahle-Backdahl M., Sandstedt B., Bruce K., Lindahl A., Jimenez M.G., Vega J.A., Lopez-Otin C. Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis. Lab. Invest. 1997, 76:717-728.
202. Okada Y., Naka K., Kawamura K., Matsumoto T., Nakanishi I., Fujimoto N., Sato H., Seiki M. Localization of matrix metalloproteinase-9 (92-kilodalton gelatinase/type IV collagenase, gelatinase B) in osteoclasts-implications for bone resorption. Lab. Invest. 1995, 72.